Alacris offers unique integrated analysis tools for oncogenomics

Alacris Theranostics has a strong background in oncogenomics and employs a wide portfolio of experimental and bioinformatics approaches focused on Next Generation Sequencing (NGS) technologies, addressing genome, exome, transcriptome and epigenome analysis, microRNA, and non-coding RNA identification as well as systems biology of cancer and personalised therapy.

Our unique integrative approach is based on a systems level data integration of NGS data coupled to biological pathway analysis, in silico modelling of individual tumours and drug response prediction (proprietary ModCellTM system). Using our own certified sequencing facility (Illumina HiSeq2500 CSPro, Roche 454 and Agilent) and the latest IT infrastructure, we can offer a comprehensive workflow from the handling of fresh or formalin-fixed, paraffin-embedded (FFPE) tissue samples to the delivery of extensive molecular analysis presented in user-friendly reports.

 

Primary Data Analysis

Assembly, mapping to a reference genome and quality control of sequencing data

Genome Analysis

Variant analysis of sequencing data:

  • Single nucleotide variants and short insertions / deletions and their functional annotation
  • Copy-number analysis including amplifications and deleted regions
  • Loss of heterozygosity

Transcriptome Analysis

  • Pre-processing and quality control of microarray and/or NGS data- Expression of coding and non-coding genes

  • Strand-specific expression

  • Differential expression analysis
  • Detection and analysis of gene fusion transcripts (e.g. resulting from translocation, chromosomal inversion or interstitial deletions)
  • miRNA profiling and target identification

Epigenome Analysis

  • DNA methylation analysis

Final Analysis results

 

SeqPipeline